Jacob Bell

3 weeks ago | biopharmadive.com | Jacob Bell

The amount of funding going into biotechnology companies has fallen off over the last couple months, a trend the investment bank Jefferies pins on Trump administration policies aimed at gutting the agencies responsible for conducting and regulating drug research. Looking at financial data from FactSet, Jefferies analysts found biotech funding in May was down 57%, to just over $2.7 billion, compared to the same time last year.

3 weeks ago | pharmavoice.com | Jacob Bell

This audio is auto-generated. Please let us know if you have feedback. Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion. Blueprint’s research revolves around an enzyme made by a gene called KIT. This “tyrosine kinase” enzyme helps control cell development, division and survival, so if it mutates, it can spur the type of uncontrolled cell growth seen in cancer and some rare diseases.

3 weeks ago | biopharmadive.com | Jacob Bell

Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion. Blueprint’s research revolves around an enzyme made by a gene called KIT. This “tyrosine kinase” enzyme helps control cell development, division and survival, so if it mutates, it can spur the type of uncontrolled cell growth seen in cancer and some rare diseases.

1 month ago | pharmavoice.com | Jacob Bell |Jacob Bell

This audio is auto-generated. Please let us know if you have feedback. Eli Lilly is wagering up to $1 billion on a private biotechnology company developing new, non-opioid pain drugs that have already caught the attention of other large pharmaceutical firms. Per an announcement Tuesday, Lilly plans to acquire SiteOne Therapeutics in an all-cash deal. The companies aren’t disclosing how much money is being exchanged upfront or when they expect the transaction to close.

1 month ago | biopharmadive.com | Jacob Bell

Eli Lilly is wagering up to $1 billion on a private biotechnology company developing new, non-opioid pain drugs that have already caught the attention of other large pharmaceutical firms. Per an announcement Tuesday, Lilly plans to acquire SiteOne Therapeutics in an all-cash deal. The companies aren’t disclosing how much money is being exchanged upfront or when they expect the transaction to close.